The Nrf2-Keap1 pathway participated in the prevention of metabolic disorders in NAFLD, and RES could activate Nrf2 signaling to inhibit lipogenesis [115]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.